Stocklytics Platform
Asset logo for symbol DGX
Quest Diagnostics
DGX52
$147.99arrow_drop_down1.85%-$2.79
S&P500
Asset logo for symbol DGX
DGX52

$147.99

arrow_drop_down1.85%
Key Stats
Open$152.11
Prev. Close$152.13
EPS7.40
Next Earnings DateJan 21, 2025
LOWHIGH
Day Range150.42
152.49
52 Week Range120.10
159.36
Ratios
EPS7.40
Fundamentals
Industry average yield2.89%
Last Dividend pay dateOct 21, 2024

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

DGX-
US Healthcare Sector-
US Market-
warning

DGX / Market

DGX lose to the US Market which returned 1.73% over the last twenty four hours.
warning

DGX / Healthcare Sector

DGX lose to the US Healthcare sector which returned 1.88% over the last twenty four hours.

Quest Diagnostics (DGX) Statistics

Quest Diagnostics Inc (DGX) is a leading provider of diagnostic testing, information, and services. As of the latest statistics, the stock has shown a steady growth trajectory. With a market capitalization of over $15 billion, Quest Diagnostics Inc is considered a stable investment option. The valuation metrics of DGX stock also indicate its promising potential. The price-to-earnings ratio is favorable, suggesting that the stock is undervalued. Additionally, the price-to-sales ratio is also favorable, indicating that investors are willing to pay a premium for Quest Diagnostics Inc shares. These valuation metrics further support the attractiveness of DGX stock as an investment opportunity.
When it comes to fundamentals, Quest Diagnostics Inc demonstrates its strength. The company has a solid revenue per share, which is an important indicator of its financial health. This metric shows how much revenue the company generates for each outstanding share of its stock. In the case of Quest Diagnostics Inc, the revenue per share is robust, reflecting its ability to generate sufficient income. Furthermore, the enterprise to EBITDA ratio, which measures the company's profitability, is favorable. This suggests that Quest Diagnostics Inc is able to generate substantial earnings before taxes, interest, depreciation, and amortization. These fundamentals position DGX as a strong player in the market.
add Quest Diagnostics  to watchlist

Keep an eye on Quest Diagnostics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How much debt does Quest Diagnostics (DGX) have?

Quest Diagnostics (DGX) has a total debt of $5.09B. The net debt, which accounts for cash and cash equivalents against the total debt, is $4.82B.
help

How has Quest Diagnostics (DGX) stock's performance compared to its sector and the market over the past year?

Over the past year, Quest Diagnostics (DGX) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 34.17%, Quest Diagnostics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 67.61%, it has fallen short of the market average. This comparison highlights Quest Diagnostics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Quest Diagnostics (DGX) stock?

The PE (Price to Earnings) ratio of Quest Diagnostics (DGX) is currently 20. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.
help

What is the EPS of Quest Diagnostics (DGX) stock?

The Earnings Per Share (EPS) for Quest Diagnostics (DGX), calculated on a diluted basis, is $7.4. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Quest Diagnostics (DGX) stock?

The operating margin for Quest Diagnostics (DGX) is 15.52%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Quest Diagnostics (DGX) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Quest Diagnostics (DGX) is $1.75B. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media